RESEARCH





Association between interpregnancy interval and maternal and neonatal adverse outcomes in women with a cesarean delivery: a population-based study

Hong Dong^{1†}, Jinghan Chi^{2†}, Wei Wang³ and Lei Liu^{4*}

Abstract

Background Interpregnancy interval (IPI) has been linked with several maternal and neonatal adverse events in the general population. However, the association between IPI and maternal and neonatal outcomes in women whose first delivery was by cesarean delivery is unclear. We aimed to investigate the association between IPI after cesarean delivery and the risk of maternal and neonatal adverse events.

Methods Women (aged \geq 18 years) whose first delivery was cesarean delivery with 2 consecutive singleton pregnancies from the National Vital Statistics System (NVSS) database between 2017 and 2019 were included in this retrospective cohort study. In this post-hoc analysis, logistic regression analyses were used to examine IPI (\leq 11, 12–17, 18–23 [reference], 24–35, 36–59, and \geq 60 months) in relation to the risk of repeat cesarean delivery, maternal adverse events (maternal transfusion, ruptured uterus, unplanned hysterectomy, and admission to an intensive care unit), and neonatal adverse events (low birthweight, premature birth, Apgar score at 5 min < 7, and abnormal conditions of the newborn). Stratified analysis based on age (< 35 and \geq 35 years) and previous preterm birth.

Results We included 792,094 maternities, 704,244 (88.91%) of which underwent a repeat cesarean delivery, 5,246 (0.66%) women had adverse events, and 144,423 (18.23%) neonates had adverse events. After adjusting for confounders, compared to an IPI of 18–23 months, the IPI of \leq 11 months [odds ratio (OR) = 1.55, 95% confidence interval (CI): 1.44–1.66], 12–17 months (OR = 1.38, 95%CI: 1.33–1.43), 36–59 months (OR = 1.12, 95%CI: 1.10–1.15), and \geq 60 months (OR = 1.19, 95%CI: 1.16–1.22) were associated with an increased risk of repeat cesarean delivery. In terms of maternal adverse events, only IPI of \geq 60 months (OR = 0.85, 95%CI: 0.76–0.95) was observed to be associated with decreased risk of maternal adverse events in women aged < 35 years. In analysis of neonatal adverse events, IPI of \leq 11 months (OR = 1.14, 95%CI: 1.07–1.21), 12–17 months (OR = 1.07, 95%CI: 1.03–1.10), and \geq 60 months (OR = 1.05, 95%CI: 1.02–1.08) were related to an increased risk of neonatal adverse events.

Conclusion Both short and long IPI were associated with an increased risk of repeat cesarean delivery and neonatal adverse events, and women < 35 years may benefit from a longer IPI.

 $^{\dagger}\mbox{Hong}$ Dong and Jinghan Chi contributed equally to this work and as co-first authors.

*Correspondence: Lei Liu liulei11260@outlook.com Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Keywords Interpregnancy interval, Cesarean delivery, Maternal outcome, Neonatal events

Background

Interpregnancy interval (IPI, intervals between delivery and subsequent conception) is a potentially modifiable risk factor for adverse neonatal and maternal outcomes [1, 2]. Epidemiological evidence suggested that IPI has an impact on maternal and neonatal morbidity [3, 4]. Short IPI (less than 18 months) has been found to be associated with maternal infection and death, preterm birth, small for gestational age and low birth weight infants, neonatal intensive care unit (NICU) admissions, and neonatal death [5-8]. Long IPI (60 months or above) was associated with maternal preeclampsia and gestational diabetes, as well as preterm birth, low birthweight, admission to the NICU, and stillbirth in newborns [2, 5, 9, 10]. Based on these adverse events, the World Health Organization currently recommends that the IPI should be at least 2 years [11].

Previous studies have reported the relationship between IPI and maternal and neonatal outcomes in subsequent pregnancies, but they did not consider the possible impact of the model of the first delivery [5, 9, 12]. The delivery model of the first pregnancy may influence the outcomes of subsequent pregnancies [13]. Clark et al. demonstrated that cesarean delivery was more likely to cause maternal morbidity and mortality than vaginal delivery in low-risk pregnancies [14]. Kjerulff et al. showed that cesarean delivery was also associated with a reduced likelihood of subsequent live birth compared with vaginal delivery [15]. Cesarean delivery is reported to occur in approximately one-third of pregnant women in the United States each year [16]. In addition, women who had a previous cesarean delivery were more likely to have a subsequent cesarean delivery [17], while those who had a previous vaginal birth were more likely to have a subsequent vaginal birth [18]. Several studies have shown that short IPI after cesarean delivery were associated with an increased risk of maternal uterine rupture in subsequent pregnancies [19–21]. However, the effect of IPI after cesarean delivery on other maternal and neonatal outcomes in subsequent pregnancies is poorly understood. And no recommendation exists for the optimal IPI after cesarean delivery.

Therefore, this study aimed to assess the association between IPI after cesarean delivery and the risks of repeat cesarean delivery, maternal and neonatal adverse events in the subsequent pregnancy.

Methods

Data source and participants

We conducted a retrospective cohort study and used data from the National Vital Statistics System (NVSS) database between 2017 and 2019. The NVSS database (https://www.cdc.gov/nchs/nvss/about_nvss.htm) is a decentralized, cooperative system completed by the National Center for Health Statistics (NCHS) and 57 registration areas [the 50 States, 2 cities (Washington, DC, and New York City), and 5 territories (Puerto Rico, the Virgin Islands, Guam, American Samoa, and the Commonwealth of the Northern Mariana Islands)] containing vital statistics on birth, deaths, marriages, divorces, and fetal deaths. Medical and health information for maternal and neonatal is included in the medical records. We limited the analytical cohort to the following women: (1) with 2 consecutive singleton pregnancies; (2) whose first delivery was by cesarean delivery; (3) aged > 18 years old; and (4) with assessment of maternal and neonatal outcomes. Women were excluded due to the following criteria: (1) missing information of IPI; (2) gestational age was recorded as < 20 or ≥ 45 weeks; (3) with multifetal pregnancies or stillbirths; and (4) missing information of key covariates such as weight gain, pre-pregnancy body mass index (BMI), smoking status, etc. Because the medical records in the NVSS database are publicly available and the data are de-identified, this post-hoc analysis study was exempt from institutional review board approval.

Study outcomes

The primary outcome of this study was the effect of IPI on the risk of repeat cesarean delivery in pregnant women. The secondary outcomes were maternal adverse events and neonatal adverse events. IPI was defined as the time elapsed between a women's first live birth and her next pregnancy, which was estimated by the delivery data of the second neonatal minus its gestational age at birth. IPI was categorized into ≤ 11 months, 12–17 months, 18–23 months, 24-35 months, 36-59 months, and \geq 60 months, with 18–23 months as the reference category [22]. Maternal adverse events included maternal transfusion, ruptured uterus, unplanned hysterectomy, and admission to an intensive care unit (ICU), and the occurrence of one of these events was defined as maternal adverse events. Neonatal adverse events included low birthweight (birth weight less than 2,500 g), premature birth (delivery less than 37 completed weeks of gestation), Apgar score at 5 min < 7, and abnormal conditions

of the newborn (assisted ventilation required immediately following delivery, assisted ventilation required for more than six hours, NICU admission, newborn given surfactant replacement therapy, antibiotics received by the newborn for suspected neonatal sepsis, seizure or serious neurologic dysfunction), and the occurrence of one of these events was defined as neonatal adverse events.

Variables

Data on maternal second singleton pregnancies were collected. Maternal characteristics included age, race (White, Black, Asian, and others), education level (less than high school, high school, more than high school, and missing), marital status (married, unmarried, and missing), weight gain, smoking before pregnancy (yes and no), smoking during pregnancy (yes and no), prenatal care (yes and no), pre-pregnancy BMI, pre-pregnancy diabetes (yes and no), gestational diabetes (yes and no), pre-pregnancy hypertension (yes and no), gestation hypertension (yes and no), eclampsia (yes and no), assisted reproductive treatment (yes and no), gestational age, clinical chorioamnionitis or maternal fever during labor (yes and no), previous preterm birth (yes and no), method of delivery (vaginal delivery and cesarean delivery), and maternal adverse events (maternal transfusion, ruptured uterus, unplanned hysterectomy, and admission to ICU). Neonatal characteristics collected neonatal adverse events (low birth weight, premature birth, Apgar score at 5 min <7, and abnormal conditions of the newborn).

Statistical analysis

Data were expressed as mean and standard deviation (SD), median and quartile [M (Q1, Q3)] or number and percentage [n (%)]. Student's t test, analysis of variance, and Kruskal-Wallis test were used for the comparison of quantitative data between groups. Chi-square test or rank sum test was used for the comparison of enumeration data. Univariate logistic regression analysis was utilized to screen for confounders associated with cesarean delivery, maternal and neonatal adverse events, where statistically significant variables were included as confounders for adjustment in multivariate logistic regression analysis. The covariates related to cesarean delivery, maternal adverse events, and neonatal adverse events were similar in the univariate logistic regression analysis and thus the same confounders were adjusted for in the multivariate logistic regression analysis (Supplement Tables 1-3). Multivariate logistic regression analysis was used to analyze the association between IPI and the risks of cesarean delivery, maternal and neonatal adverse events by adjusting for age, race, education level, marital status, weight gain, smoking before pregnancy, smoking during pregnancy, prenatal care, pre-pregnancy BMI, pre-pregnancy diabetes, gestational diabetes, pre-pregnancy hypertension, gestation hypertension, eclampsia, assisted reproductive treatment, gestational age, clinical chorioamnionitis or maternal fever during labor, and previous preterm birth. Odds ratio (OR) and 95% confidence interval (CI) were used to assess effect values. Stratified analyses based on maternal age (<35 and \geq 35 years) and previous preterm birth were used to further analyze the relationship between IPI and the risk of cesarean delivery, maternal and neonatal adverse events. Analyses were performed with the SAS 9.3 software (SAS Institute Inc., Cary, NC, USA). Statistical tests were two-sided, and *P*<0.05 indicates statistical significance.

Results

Characteristics of participants

There were 11,423,870 maternities in the NVSS database during our study period. After excluding 7,786,080 maternities who did not have 2 consecutive singleton pregnancies, 2,736,613 maternities whose first delivery was not a cesarean delivery, 1,112 maternities younger than 18 years of age, 1,091 maternities who were not assessed for maternal and neonatal outcomes, and 106,874 maternities who were missing key covariates, a total of 792,094 maternities were included in this study (Fig. 1). Of these 792,094 women, the mean age was 30.42 ± 5.36 years, the mean prepregnancy BMI was 28.66 ± 7.37 kg/m², and 578,146(72.99%) were white. Approximately 1.5% (12,176) of deliveries occurred after an IPI of ≤ 11 months, 7.2% (56,716) after an IPI of 12–17 months, 12.4% (97,840) after an IPI of 18-23 months, 23.5% (186,588) after an IPI of 24-35 months, 26.3% (208,005) after an IPI of 36-59 months, and 29.1% (230,769) after an IPI of > 60 months. There were 37,467 (4.73%) women who had a previous preterm birth, 704,244 (88.91%) women who underwent a repeat cesarean delivery, 5,246 (0.66%) women who had adverse events, and 144,423 (18.23%) neonates who had adverse events (Table 1). The proportions of repeat cesarean delivery, maternal adverse events, and neonatal adverse events by IPI were shown in Fig. 2.

Effect of IPI on the risk of repeat cesarean delivery

Table 2 shows the association between IPI and the risk of repeat cesarean delivery. After adjusting for confounders, compared to an IPI of 18–23 months, the IPI of \leq 11 months (OR=1.55, 95%CI: 1.44–1.66), 12–17 months (OR=1.38, 95%CI: 1.33–1.43), 36–59 months (OR=1.12, 95%CI: 1.10–1.15), and \geq 60 months (OR=1.19, 95%CI: 1.16–1.22) were

Table 1 Characteristics of the study population by interpregnancy interval (IPI)

		Interpregnanc	y interval						
Variables	Total (n = 792,094)	\leq 11 month (n = 12,176)	12–17 month (n = 56,716)	18–23 month (n=97,840)	24–35 month (n = 186,588)	36–59 month (n = 208,005)	\geq 60 month (n = 230,769)	Statistics	Р
Age, year, mean \pm SD	30.42±5.36	26.53 ± 5.70	28.14±5.76	29.69±5.52	30.36±5.33	30.32±5.29	31.64±4.90	F=6357.89	< 0.001
Race, n (%)									
White	578,146 (72.99)	8166 (67.07)	41,196 (72.64)	76,140 (77.82)	145,666 (78.07)	152,414 (73.27)	154,564 (66.98)	$\chi^2 = 12,146.74$	< 0.001
Black	116,083 (14.66)	2823 (23.18)	9904 (17.46)	11,748 (12.01)	19,647 (10.53)	27,413 (13.18)	44,548 (19.30)		
Other	24,995 (3.16)	578 (4.75)	2355 (4.15)	3031 (3.10)	5362 (2.87)	6262 (3.01)	7407 (3.21)		
Asian	72,870 (9.20)	609 (5.00)	3261 (5.75)	6921 (7.07)	15,913 (8.53)	21,916 (10.54)	24,250 (10.51)		
Education lev	el, n (%)								
Less than high school	15,163 (1.91)	239 (1.96)	860 (1.52)	1263 (1.29)	2249 (1.21)	3624 (1.74)	6928 (3.00)	$\chi^2 = 15,553.44$	< 0.001
High school	233,851 (29.52)	5902 (48.47)	20,446 (36.05)	24,433 (24.97)	42,785 (22.93)	58,589 (28.17)	81,696 (35.40)		
More than high school	534,388 (67.47)	5931 (48.71)	34,881 (61.50)	71,244 (72.82)	139,611 (74.82)	143,536 (69.01)	139,185 (60.31)		
Missing	8692 (1.10)	104 (0.85)	529 (0.93)	900 (0.92)	1943 (1.04)	2256 (1.08)	2960 (1.28)		
Marital status,	n (%)								
Married	460,078 (58.08)	5215 (42.83)	30,791 (54.29)	63,787 (65.20)	125,514 (67.27)	125,909 (60.53)	108,862 (47.17)	$\chi^2 = 26,705.16$	< 0.001
Unmarried	224,320 (28.32)	5787 (47.53)	19,419 (34.24)	22,027 (22.51)	36,328 (19.47)	53,066 (25.51)	87,693 (38.00)		
Missing	107,696 (13.60)	1174 (9.64)	6506 (11.47)	12,026 (12.29)	24,746 (13.26)	29,030 (13.96)	34,214 (14.83)		
Weight gain, pounds, M (Q_1, Q_2)	28.00 (19.00,37.00)	26.00 (17.00,35.00)	27.00 (18.00,35.00)	29.00 (20.00,37.00)	29.00 (20.00,37.00)	28.00 (19.00,37.00)	28.00 (18.00,38.00)	$\chi^2 = 1245.86$	< 0.001
Smoking befo	ore pregnancy, n (%	b)							
No	733,610 (92.62)	10,927 (89.74)	52,364 (92.33)	92,779 (94.83)	177,324 (95.04)	193,877 (93.21)	206,339 (89.41)	$\chi^2 = 6017.56$	< 0.001
Yes	58,484 (7.38)	1249 (10.26)	4352 (7.67)	5061 (5.17)	9264 (4.96)	14,128 (6.79)	24,430 (10.59)	,	
Smoking duri	ng pregnancy, n (%	6)							
No	747,537 (94.37)	11,120 (91.33)	53,186 (93.78)	93,946 (96.02)	179,767 (96.34)	197,581 (94.99)	211,937 (91.84)	$\chi^2 = 5055.38$	< 0.001
Yes	44,557 (5.63)	1056 (8.67)	3530 (6.22)	3894 (3.98)	6821 (3.66)	10,424 (5.01)	18,832 (8.16)	,	
Prenatal care,	n (%)								
No	6562 (0.83)	230 (1.89)	695 (1.23)	805 (0.82)	1240 (0.66)	1485 (0.71)	2107 (0.91)	$\chi^2 = 389.80$	< 0.001
Yes	785,532 (99.17)	11,946 (98.11)	56,021 (98.77)	97,035 (99.18)	185,348 (99.34)	206,520 (99.29)	228,662 (99.09)		
Pre-	28.66±7.37	30.20 ± 7.88	29.06±7.48	27.97±7.11	27.80±7.03	28.59±7.32	29.54±7.60	F = 1487.17	< 0.001
BMI, kg/m², mean±SD									
Pre-pregnanc	y diabetes, n (%)								
No	779,451 (98.40)	11,951 (98.15)	55,896 (98.55)	96,627 (98.76)	184,228 (98.74)	204,914 (98.51)	225,835 (97.86)	$\chi^2 = 670.14$	< 0.001
Yes	12,643 (1.60)	225 (1.85)	820 (1.45)	1213 (1.24)	2360 (1.26)	3091 (1.49)	4934 (2.14)		
Gestational di	abetes, n (%)								
No	725,733 (91.62)	11,243 (92.34)	52,746 (93.00)	90,994 (93.00)	173,293 (92.87)	190,448 (91.56)	207,009 (89.70)	$\chi^2 = 1879.98$	< 0.001
Yes	66,361 (8.38)	933 (7.66)	3970 (7.00)	6846 (7.00)	13,295 (7.13)	17,557 (8.44)	23,760 (10.30)		
Pre-pregnanc	y hypertension, n (%)							
No	769,955 (97.21)	11,751 (96.51)	55,199 (97.33)	95,701 (97.81)	182,528 (97.82)	202,763 (97.48)	222,013 (96.21)	$\chi^2 = 1327.37$	< 0.001
Yes	22,139 (2.79)	425 (3.49)	1517 (2.67)	2139 (2.19)	4060 (2.18)	5242 (2.52)	8756 (3.79)		
Gestation hyp	ertension, n (%)								
No	741,155 (93.57)	11,234 (92.26)	53,157 (93.72)	92,370 (94.41)	176,039 (94.35)	194,814 (93.66)	213,541 (92.53)	$\chi^2 = 752.12$	< 0.001
Yes	50,939 (6.43)	942 (7.74)	3559 (6.28)	5470 (5.59)	10,549 (5.65)	13,191 (6.34)	17,228 (7.47)		
Eclampsia, n (%)								
No	790,160 (99.76)	12,139 (99.70)	56,578 (99.76)	97,636 (99.79)	186,257 (99.82)	207,509 (99.76)	230,041 (99.68)	$\chi^2 = 89.49$	< 0.001
Yes	1934 (0.24)	37 (0.30)	138 (0.24)	204 (0.21)	331 (0.18)	496 (0.24)	728 (0.32)		
Assisted repro	oductive treatment	, n (%)							
No	782,824 (98.83)	12,145 (99.75)	56,377 (99.40)	96,504 (98.63)	183,671 (98.44)	205,346 (98.72)	228,781 (99.14)	$\chi^2 = 741.76$	< 0.001
Yes	9270 (1.17)	31 (0.25)	339 (0.60)	1336 (1.37)	2917 (1.56)	2659 (1.28)	1988 (0.86)		

Interpregnancy interval

 \leq 11 month

(n = 12,176)

 38.02 ± 2.55

12-17 month

(n = 56,716)

 38.53 ± 2.08

Table 1 (continued)

Total

(n = 792,094)

 38.52 ± 1.96

Variables

Gestational

18–23 month (n=97,840)	24–35 month (n = 186,588)	36–59 month (n = 208,005)	≥ 60 month (n=230,769)	Statistics	Р
38.62±1.88	38.65±1.80	38.55±1.89	38.36±2.08	F=670.30	< 0.001
97,105 (99.25) 735 (0.75)	185,227 (99.27) 1361 (0.73)	206,399 (99.23) 1606 (0.77)	228,965 (99.22) 1804 (0.78)	$\chi^2 = 41.94$	< 0.001

age, week, mean±SD									
Clinical cho	rioamnionitis or mate	ernal fever during l	abor, n (%)						
No	786,200 (99.26)	12,125 (99.58)	56,379 (99.41)	97,105 (99.25)	185,227 (99.27)	206,399 (99.23)	228,965 (99.22)	$\chi^2 = 41.94$	< 0.001
Yes	5894 (0.74)	51 (0.42)	337 (0.59)	735 (0.75)	1361 (0.73)	1606 (0.77)	1804 (0.78)		
Previous pre	eterm birth, n (%)								
No	754,627 (95.27)	11,241 (92.32)	53,573 (94.46)	93,460 (95.52)	178,306 (95.56)	198,460 (95.41)	219,587 (95.15)	$\chi^2 = 383.01$	< 0.001
Yes	37,467 (4.73)	935 (7.68)	3143 (5.54)	4380 (4.48)	8282 (4.44)	9545 (4.59)	11,182 (4.85)		
Method of a	delivery, n (%)								
Vaginal delivery	87,850 (11.09)	1010 (8.30)	5515 (9.72)	12,788 (13.07)	24,303 (13.02)	23,019 (11.07)	21,215 (9.19)	$\chi^2 = 2143.50$	< 0.001
Cesarean delivery	704,244 (88.91)	11,166 (91.70)	51,201 (90.28)	85,052 (86.93)	162,285 (86.98)	184,986 (88.93)	209,554 (90.81)		
Maternal ac	verse events, n (%)								
No	786,848 (99.34)	12,071 (99.14)	56,301 (99.27)	97,182 (99.33)	185,404 (99.37)	206,686 (99.37)	229,204 (99.32)	$\chi^2 = 17.29$	0.004
Yes	5246 (0.66)	105 (0.86)	415 (0.73)	658 (0.67)	1184 (0.63)	1319 (0.63)	1565 (0.68)		
Maternal tra	insfusion, n (%)								
No	788,712 (99.57)	12,112 (99.47)	56,459 (99.55)	97,387 (99.54)	185,801 (99.58)	207,156 (99.59)	229,797 (99.58)	$\chi^2 = 8.72$	0.121
Yes	3382 (0.43)	64 (0.53)	257 (0.45)	453 (0.46)	787 (0.42)	849 (0.41)	972 (0.42)		
Ruptured u	erus, n (%)								
No	791,312 (99.90)	12,156 (99.84)	56,630 (99.85)	97,719 (99.88)	186,391 (99.89)	207,814 (99.91)	230,602 (99.93)	$\chi^2 = 45.72$	< 0.001
Yes	782 (0.10)	20 (0.16)	86 (0.15)	121 (0.12)	197 (0.11)	191 (0.09)	167 (0.07)		
Unplanned	hysterectomy, n (%)								
No	791,503 (99.93)	12,169 (99.94)	56,677 (99.93)	97,769 (99.93)	186,457 (99.93)	207,846 (99.92)	230,585 (99.92)	$\chi^2 = 2.18$	0.823
Yes	591 (0.07)	7 (0.06)	39 (0.07)	71 (0.07)	131 (0.07)	159 (0.08)	184 (0.08)		
Admission t	o ICU, n (%)								
No	790,665 (99.82)	12,150 (99.79)	56,619 (99.83)	97,698 (99.85)	186,309 (99.85)	207,636 (99.82)	230,253 (99.78)	$\chi^2 = 41.67$	< 0.001
Yes	1429 (0.18)	26 (0.21)	97 (0.17)	142 (0.15)	279 (0.15)	369 (0.18)	516 (0.22)		
Neonatal ac	lverse events, n(%)								
No	647,671 (81.77)	8891 (73.02)	45,712 (80.60)	81,515 (83.31)	156,834 (84.05)	171,927 (82.66)	182,792 (79.21)	$\chi^2 = 2610.49$	< 0.001
Yes	144,423 (18.23)	3285 (26.98)	11,004 (19.40)	16,325 (16.69)	29,754 (15.95)	36,078 (17.34)	47,977 (20.79)		
Low birth w	reight, n (%)								
No	749,746 (94.65)	11,026 (90.56)	53,728 (94.73)	93,789 (95.86)	179,043 (95.96)	197,677 (95.03)	214,483 (92.94)	$\chi^2 = 2706.29$	< 0.001
Yes	42,348 (5.35)	1150 (9.44)	2988 (5.27)	4051 (4.14)	7545 (4.04)	10,328 (4.97)	16,286 (7.06)		
Premature b	pirth, n (%)								
No	714,221 (90.17)	10,049 (82.53)	50,613 (89.24)	89,233 (91.20)	171,435 (91.88)	188,987 (90.86)	203,904 (88.36)	$\chi^2 = 2554.33$	< 0.001
Yes	77,873 (9.83)	2127 (17.47)	6103 (10.76)	8607 (8.80)	15,153 (8.12)	19,018 (9.14)	26,865 (11.64)		
Apgar score	at 5 min < 7, n (%)								
No	781,028 (98.60)	11,905 (97.77)	55,861 (98.49)	96,595 (98.73)	184,295 (98.77)	205,258 (98.68)	227,114 (98.42)	$\chi^2 = 182.29$	< 0.001
Yes	11,066 (1.40)	271 (2.23)	855 (1.51)	1245 (1.27)	2293 (1.23)	2747 (1.32)	3655 (1.58)		
Abnormal c	onditions of the new	/born, n (%)							
No	707,257 (89.29)	10,334 (84.87)	50,395 (88.85)	88,285 (90.23)	168,667 (90.40)	186,685 (89.75)	202,891 (87.92)	$\chi^2 = 1088.64$	< 0.001
Yes	84.837 (10.71)	1842 (15.13)	6321 (11.15)	9555 (9.77)	17 921 (9 60)	21.320 (10.25)	27 878 (12 08)		

associated with an increased risk of repeat cesarean delivery, whereas an IPI of 24–35 months may not be related to a risk of repeat cesarean delivery (P=0.159). Among women of different ages, the IPI of \leq 11 months, 12–17 months, 36–59 months, and \geq 60 months were still

associated with an increased risk of repeat cesarean delivery in maternities aged < 35 years (all P < 0.001), while an IPI of 24–35 months (OR = 0.92, 95%CI: 0.86–0.98) was related to a decreased risk of repeat cesarean delivery in maternities aged \geq 35 years. Among women with and



Fig. 1 Flowchart showing the selection of the study population

without previous preterm births, the IPI of \leq 11 months, 12–17 months, 36–59 months, and \geq 60 months were associated with an increased risk of repeat cesarean delivery (all *P*<0.05).

The association between IPI and the risk of repeat cesarean delivery was further analyzed in women who underwent a trial of labor after cesarean (TOLAC). A total of 133,970 women underwent TOLAC, of which 46,042 (34.37%) women underwent repeat cesarean delivery (Table 3). After adjusting for confounders, compared to an IPI of 18–23 months, the IPI of \leq 11 months (OR = 1.21, 95%CI: 1.08–1.35), 12–17 months (OR = 1.15, 95%CI: 1.08–1.21), 36–59 months (OR = 1.05, 95%CI: 1.01–1.10), and \geq 60 months (OR = 1.16, 95%CI: 1.11–1.21) were still related to an increased risk of repeat cesarean delivery in women who underwent TOLAC, while an IPI of 24–35 months may not be related to a risk of repeat cesarean delivery (P=0.483).

Association between IPI and maternal adverse events

The impact of IPI on maternal adverse events was demonstrated in Table 4. After adjusting for confounders, IPI of ≤ 11 months, 12–17 months, 24–35 months, 36–59 months, and ≥ 60 months may not be associated with the risk of maternal adverse events compared with IPI of 18–23 months (all P>0.05). Stratified analyses based on age and previous preterm births showed that IPI of \geq 60 months (OR=0.85, 95%CI: 0.76–0.95) was observed to be associated with decreased risk of maternal adverse events only in women aged < 35 years.

In the analysis of the effect of IPI on specific maternal adverse events, IPI of 36–59 months (OR=0.88, 95%CI: 0.78–0.99) and \geq 60 months (OR=0.86, 95%CI: 0.76–0.97) were associated with a decreased risk of maternal transfusion. IPI of \geq 60 months was related to a decreased risk of the ruptured uterus in women aged < 35 years (OR=0.59, 95%CI: 0.45–0.78) and without previous pretern birth (OR=0.65, 95%CI: 0.50–0.86). No association was observed between IPI and the risk of unplanned hysterectomy (all *P*>0.05). IPI of \geq 60 months (OR=1.56, 95%CI: 1.01–2.41) was found to be associated with an increased risk of ICU admission in women aged \geq 35 years.

Association between IPI and neonatal adverse events

Table 5 demonstrates the impact of IPI on neonatal adverse events. After adjusting for confounders, IPI of \leq 11 months (OR = 1.14, 95%CI: 1.07–1.21), 12–17 months (OR = 1.07, 95%CI: 1.03–1.10), and \geq 60 months (OR = 1.05, 95%CI: 1.02–1.08) were









Cesarean delivery	Interpregnancy	interval									
	≤ 11 month		12–17 month		18–23 month	24–35 month		36–59 month		≥ 60 month	
	OR (95% CI)	٩	OR (95% CI)	٩	OR (95% CI)	OR (95% CI)	٩	OR (95% CI)	٩	OR (95% CI)	Р
Total population	1.55 (1.44–1.66)	< 0.001	1.38 (1.33–1.43)	< 0.001	1.00 [Ref]	0.98 (0.96–1.01)	0.159	1.12 (1.10–1.15)	< 0.001	1.19 (1.16–1.22)	< 0.001
Age group											
< 35	1.47 (1.36–1.58)	< 0.001	1.34 (1.29–1.40)	< 0.001	1.00 [Ref]	1.01 (0.98–1.04)	0.431	1.17 (1.14–1.21)	< 0.001	1.28 (1.24–1.31)	< 0.001
≥ 35	1.77 (1.34–2.33)	< 0.001	1.37 (1.24–1.53)	< 0.001	1.00 [Ref]	0.92 (0.86–0.98)	0.008	1.02 (0.96–1.09)	0.460	1.23 (1.15–1.31)	< 0.001
Previous preterm birth	is group										
No	1.56 (1.44–1.68)	< 0.001	1.38 (1.33–1.44)	< 0.001	1.00 [Ref]	0.98 (0.96–1.01)	0.162	1.12 (1.09–1.15)	< 0.001	1.20 (1.16–1.23)	< 0.001
Yes	1.52 (1.20–1.92)	< 0.001	1.29 (1.12–1.48)	< 0.001	1.00 [Ref]	0.98 (0.88–1.09)	0.754	1.14 (1.03–1.27)	0.014	1.12 (1.01–1.25)	0.035
OR odds ratio, C/ confide gain, smoking before pri	enterval, Ref refer sgnancy, smoking du	ence; OR show ring pregnancy	s the results of multiva y, prenatal care, pre-pre- outer of material form	ariate logistic r egnancy BMI,	egression analysis al pre-pregnancy diab	fter adjusting for age (etes, gestational diabe	(unadjusted stes, pre-pre	in age group analysis) gnancy hypertension,	, race, education gestation hyp	on level, marital status ertension, eclampsia,	, weight assisted

~
\sim
5
ž
÷
Ð
$\overline{\mathbf{O}}$
Ē
F
2
σ
S
g
0
Ħ
×
5
Ψ
4
Ö
Ň
5
·Ξ
4
Ψ
÷
-
0
<u> </u>
σ
\subseteq
Δ_
-
_
g
~
5
Ę
\sim
2
F
č
<u> </u>
_
ğ
reg
oreg
rpreg
erpreg
Iterpreg
interpreg
n interpreg
en interpreg
sen interpreg
veen interpreg
ween interpreg
etween interpreg
oetween interpreg
between interpreg
n between interpreg
on between interpreg
tion between interpreg
ation between interpreg
ciation between interpreg
ociation between interpreg
sociation between interpreg
ssociation between interpreg
Association between interpreg
Association between interpreg
2 Association between interpreg
2 Association between interpreg
le 2 Association between interpreg
ble 2 Association between interpreg
able 2 Association between interpreg
Table 2 Association between interpreg

2 Ś 2 D, 2 5 2 2 5 5 2 ς Ω יר *OR* gaii

Variables	Women with	Repeat cesarean	Univariate analysis	5	Multivariate analys	is
	TOLAC (n)	delivery (%)	OR (95%CI)	Р	OR (95%CI)	Р
	133,970	46,042 (34.37%)				
Interpregnancy interv	val					
18–23 month	18,564	5765 (31.05%)	Ref		Ref	
≤11 month	1593	582 (36.53%)	1.28 (1.15–1.42)	< 0.001	1.21 (1.08–1.35)	0.001
12–17 month	8506	2987 (35.12%)	1.20 (1.14–1.27)	< 0.001	1.15 (1.08–1.21)	< 0.001
24–35 month	35,344	11,018 (31.17%)	1.01 (0.97–1.04)	0.777	0.99 (0.95–1.03)	0.483
36–59 month	34,923	11,881 (34.02%)	1.14 (1.10–1.19)	< 0.001	1.05 (1.01–1.10)	0.011
\geq 60 month	35,040	13,809 (39.41%)	1.44 (1.39–1.50)	< 0.001	1.16 (1.11–1.21)	< 0.001

Table 3 Association between interpregnancy interval (IPI) and risk of repeat cesarean delivery in women who underwent a trial of labor after cesarean (TOLAC)

OR odds ratio, CI confidence interval, Ref reference

Multivariate logistic regression analysis adjusted for age, race, education level, marital status, weight gain, smoking before pregnancy, smoking during pregnancy, prenatal care, pre-pregnancy BMI, pre-pregnancy diabetes, gestational diabetes, pre-pregnancy hypertension, gestation hypertension, eclampsia, assisted reproductive treatment, gestational age, clinical chorioamnionitis or maternal fever during labor, and previous preterm birth

related to an increased risk of neonatal adverse events compared with IPI of 18–23 months. Stratified analyses based on age and previous preterm births indicated that IPI of \leq 11 months and 12–17 months were observed to be associated with an increased risk of neonatal adverse events in women aged < 35 years and women without previous preterm birth, and IPI of \geq 60 months was found to be related to an increased risk of neonatal adverse events in women aged \geq 35 years and women without previous preterm birth (all *P* < 0.05).

In the analysis of the effect of IPI on specific neonatal adverse events, IPI of ≤ 11 months (OR = 1.38, 95%CI: 1.26–1.52), 12–17 months (OR=1.07, 95%CI: 1.01-1.14), 24-35 months (OR=1.07, 95%CI: 1.02-1.13), 36–59 months (OR=1.22, 95%CI: 1.17–1.28), and \geq 60 months (OR = 1.51, 95%CI: 1.44–1.58) were related to an increased risk of low birth weight. No associations of IPI with the risk of premature birth and Apgar score at 5 min <7 were found (all P > 0.05). IPI of ≤ 11 months (OR = 1.18, 95%CI: 1.11-1.25), 12 - 17months (OR = 1.07,95%CI: 1.03–1.11), and > 60 months (OR = 1.05, 95%CI: 1.02-1.08) were found to be associated with an increased risk of abnormal conditions of the neonatal.

Discussion

This study analyzed the effect of the IPI after maternal cesarean delivery on the risk of repeat cesarean delivery, maternal and neonatal adverse events. Both short and long IPIs were associated with an increased risk of repeat cesarean delivery. Long IPI was found to be related to a decreased risk of maternal adverse events in women aged < 35 years. In the association between IPI and neonatal adverse events, short and long IPIs were related to

an increased risk of neonatal adverse events, especially among women aged < 35 years.

The delivery model of the first pregnancy is associated with subsequent maternal pregnancy outcomes. Winsen et al. demonstrated that emergency cesarean delivery in the first pregnancy was related to a higher rate of preterm birth and an increased risk of admission to a neonatal unit in subsequent pregnancies compared to vaginal delivery [13]. Previous studies have explored the impact of IPI on subsequent pregnancy outcomes [5, 9, 12, 23]. Both short and long IPI were reported to be associated with increased risk of preterm birth, low, birth weight, smallfor-gestational-age birth, and neonatal ICU admission [5, 9, 24, 25]. However, previous studies have not distinguished the effect of IPI after different delivery models on subsequent pregnancy outcomes. This study analyzed the effect of maternal IPI after cesarean delivery on maternal and neonatal outcomes in subsequent pregnancies. Our results demonstrated that both short and long IPIs were associated with an increased risk of repeat cesarean delivery. This association persisted among women who experienced TOLAC. This result may be related to the fact that women who had a previous cesarean delivery were more likely to have a subsequent cesarean delivery [17]. This may also be related to the worldwide increase in the prevalence of cesarean delivery [26]. Our results showed that 88.91% of women who had a first cesarean delivery underwent a repeat cesarean delivery in subsequent pregnancies. The increase in cesarean rates is influenced by many factors including demand for cesarean delivery, advanced maternal age at first pregnancy, and a decrease in the number of patients attempting vaginal delivery after cesarean delivery [27-29]. One possible reason for the high rate of repeat cesarean delivery in women with

Outcome	Interpregnancy i	nterval									
	≤ 11 month		12~17 month		18~23 month	24~35 month		36~59 month		> 60 month	
	OR (95% CI)	٩	OR (95% CI)	٩	OR (95% CI)	OR (95% CI)	٩	OR (95% CI)	٩	OR (95% CI)	Р
Maternal adverse ev	ents										
Total population	1.01 (0.81–1.25)	0.919	1.01 (0.89–1.15)	0.827	1.00 [Ref]	0.95 (0.86–1.05)	0.347	0.92 (0.84–1.02)	0.102	0.91 (0.82–0.99)	0.052
Age group											
< 35	1.07 (0.86–1.34)	0.544	1.03 (0.90–1.18)	0.680	1.00 [Ref]	0.91 (0.82–1.02)	0.115	0.91 (0.82–1.02)	0.108	0.85 (0.76–0.95)	0.004
≥ 35	0.52 (0.21–1.29)	0.161	0.90 (0.64–1.27)	0.549	1.00 [Ref]	1.11 (0.89–1.39)	0.361	0.95 (0.76–1.18)	0.620	1.03 (0.83–1.28)	0.771
Previous preterm bi	irths group										
No	1.05 (0.83-1.32)	0.694	0.99 (0.87–1.14)	0.955	1.00 [Ref]	0.97 (0.87–1.08)	0.577	0.94 (0.84–1.04)	0.219	0.92 (0.83–1.03)	0.137
Yes	0.77 (0.43–1.37)	0.371	1.11 (0.77–1.60)	0.574	1.00 [Ref]	0.80 (0.59–1.10)	0.179	0.78 (0.57–1.06)	0.116	0.76 (0.56–1.03)	0:080
Maternal transfusior	-										
Total population	0.90 (0.68–1.18)	0.435	0.91 (0.78–1.07)	0.265	1.00 [Ref]	0.92 (0.82–1.04)	0.182	0.88 (0.78–0.99)	0.033	0.86 (0.76–0.97)	0.015
Age group											
<35	0.99 (0.75–1.30)	0.923	0.97 (0.81–1.14)	0.681	1.00 [Ref]	0.90 (0.79–1.03)	0.123	0.90 (0.79–1.02)	0.110	0.82 (0.72–0.94)	0.004
≥ 35	0.31 (0.08–1.25)	0.100	0.66 (0.42–1.03)	0.069	1.00 [Ref]	0.98 (0.75–1.27)	0.868	0.77 (0.59–1.01)	0.057	0.87 (0.67–1.12)	0.285
Previous preterm bi	irths group										
No	0.90 (0.67–1.21)	0.482	0.90 (0.76–1.06)	0.211	1.00 [Ref]	0.94 (0.83-1.07)	0.332	0.88 (0.77–0.99)	0.036	0.87 (0.77–0.99)	0.032
Yes	0.86 (0.41–1.80)	0.688	1.03 (0.64–1.68)	0.894	1.00 [Ref]	0.73 (0.48–1.11)	0.143	0.89 (0.60–1.32)	0.563	0.75 (0.50-1.12)	0.154
Ruptured uterus											
Total population	1.47 (0.91–2.38)	0.116	1.27 (0.95–1.70)	0.107	1.00 [Ref]	0.86 (0.68–1.09)	0.212	0.79 (0.63–1.01)	0.059	0.64 (0.50–0.83)	< 0.001
Age group											
< 35	1.52 (0.92–2.50)	0.099	1.26 (0.93–1.72)	0.140	1.00 [Ref]	0.79 (0.61–1.03)	0.083	0.77 (0.59–0.99)	0.046	0.59 (0.45–0.78)	< 0.001
≥ 35	0.95 (0.13-7.21)	0.961	1.28 (0.57–2.92)	0.549	1.00 [Ref]	1.18 (0.66–2.11)	0.573	0.91 (0.50–1.64)	0.749	0.84 (0.46–1.51)	0.557
Previous preterm bi	irths group										
No	1.54 (0.91–2.58)	0.105	1.27 (0.93–1.73)	0.127	1.00 [Ref]	0.84 (0.65–1.08)	0.168	0.80 (0.62–1.03)	0.087	0.65 (0.50-0.86)	0.002
Yes	1.09 (0.30–3.99)	006.0	1.24 (0.52–2.94)	0.626	1.00 [Ref]	1.05 (0.51–2.17)	0.898	0.73 (0.34–1.56)	0.415	0.58 (0.26–1.29)	0.181
Unplanned hysterec	tomy										
Total population	0.79 (0.36–1.74)	0.562	0.89 (0.58–1.37)	0.604	1.00 [Ref]	0.96 (0.70–1.30)	0.769	1.03 (0.76–1.38)	0.861	0.92 (0.68–1.24)	0.586
Age group											
< 35	0.71 (0.30–1.66)	0.424	0.77 (0.47–1.27)	0.308	1.00 [Ref]	0.91 (0.63–1.30)	0.590	1.02 (0.72–1.45)	0.914	0.99 (0.70–1.42)	0.977
≥35	0.83 (0.11–6.26)	0.853	1.17 (0.52–2.63)	0.706	1.00 [Ref]	1.16 (0.66–2.04)	0.617	1.17 (0.67–2.04)	0.578	1.18 (0.69–2.04)	0.543
Previous preterm bi	irths group										
No	0.66 (0.26–1.64)	0.369	0.92 (0.59–1.42)	0.693	1.00 [Ref]	0.92 (0.67–1.27)	0.624	1.03 (0.76–1.39)	0.863	0.90 (0.66–1.22)	0.485
Yes	1.66 (0.29–9.51)	0.568	0.68 (0.12–3.77)	0.662	1.00 [Ref]	1.41 (0.45–4.44)	0.560	1.01 (0.31–3.32)	0.982	1.24 (0.40–3.88)	0.714

 Table 4
 Effect of interpregnancy interval (IPI) on maternal adverse events

	<pre>11 month</pre>		12~17 month		18~23 month	24~35 month		36~59 month		> 60 month	
	OR (95% CI)	ط	OR (95% CI)	٩	OR (95% CI)	OR (95% CI)	٩	OR (95% CI)	٩	OR (95% CI)	٩
Admission to ICU											
Total population	0.91 (0.57–1.45)	0.687	1.08 (0.82–1.42)	0.593	1.00 [Ref]	1.02 (0.82–1.27)	0.828	1.13 (0.92–1.39)	0.257	1.16 (0.94–1.42)	0.157
Age group											
< 35	0.89 (0.54–1.46)	0.640	1.07 (0.79–1.45)	0.645	1.00 [Ref]	0.98 (0.77–1.25)	0.870	1.11 (0.88–1.40)	0.381	1.10 (0.87–1.39)	0.426
≥ 35	0.80 (0.19–3.44)	0.769	0.98 (0.49–1.96)	0.948	1.00 [Ref]	1.25 (0.78-2.01)	0.350	1.30 (0.82–2.05)	0.264	1.56 (1.01–2.41)	0.047
Previous preterm k	births group										
No	1.05 (0.63-1.73)	0.862	1.02 (0.75–1.39)	0.911	1.00 [Ref]	1.04 (0.82–1.31)	0.768	1.19 (0.95–1.49)	0.130	1.21 (0.97–1.51)	0.088
Yes	0.41 (0.12–1.43)	0.164	1.27 (0.67–2.41)	0.466	1.00 [Ref]	0.97 (0.55–1.70)	0.904	0.79 (0.45–1.39)	0.409	0.87 (0.50–1.52)	0.633
OR odds ratio, Cl confic	Jence interval, <i>Ref</i> refer	ence, <i>ICU</i> inte	ensive care unit; OR sho	ws the resu	llts of multivariate logis	stic regression analysis.	after adjusti	ng for age (unadjusted	in age grou	up analysis), race, educa	tion level,
marital status, weight 🤅	gain, smoking before pr	egnancy, sm	oking during pregnanc	cy, prenatal	care, pre-pregnancy BN	MI, pre-pregnancy diab	etes, gestati	onal diabetes, pre-preg	gnancy hype	ertension, gestation hyp	vertension,
eclampsia, assisted rep	productive treatment, go	estational ag	e, clinical chorioamnior	nitis or mat	ernal fever during laboı	r, and previous preterm	ı birth (unad	justed in previous pret	erm births g	group analysis)	

Interpregnancy interval

 Table 4 (continued)

 Outcome

Outcome	Interpregnancy ir	nterval									
	<pre>< 11 month</pre>		12~17 month		18~23 month	24~35 month		36 ~ 59 month		2 60 month	
	OR (95% CI)	٩	OR (95% CI)	٩	OR (95% CI)	OR (95% CI)	٩	OR (95% CI)	٩	OR (95% CI)	٩
Neonatal adverse e	vents										
Total population	1.14 (1.07–1.21)	< 0.001	1.07 (1.03–1.10)	< 0.001	1.00 [Ref]	0.99 (0.97–1.02)	0.714	0.99 (0.97–1.02)	0.732	1.05 (1.02–1.08)	< 0.001
Age group											
< 35	1.14 (1.07–1.21)	< 0.001	1.06 (1.02–1.11)	0.002	1.00 [Ref]	0.99 (0.97–1.03)	0.761	0.99 (0.96–1.01)	0.321	1.03 (1.01–1.06)	0.089
≥ 35	1.15 (0.96–1.37)	0.130	1.06 (0.97–1.16)	0.164	1.00 [Ref]	0.99 (0.94–1.06)	0.941	1.04 (0.98–1.10)	0.222	1.10 (1.04–1.17)	< 0.001
Previous preterm k	oirths group										
No	1.14 (1.07–1.21)	< 0.001	1.06 (1.02–1.10)	0.002	1.00 [Ref]	0.99 (0.97–1.02)	0.733	0.99 (0.97–1.02)	0.683	1.05 (1.02-1.08)	< 0.001
Yes	1.17 (0.95–1.44)	0.135	1.13 (0.99–1.29)	0.071	1.00 [Ref]	0.99 (0.89–1.10)	0.891	1.01 (0.91–1.12)	0.856	1.03 (0.93–1.14)	0.592
Low birth weight											
Total population	1.38 (1.26–1.52)	< 0.001	1.07 (1.01–1.14)	0.035	1.00 [Ref]	1.07 (1.02–1.13)	0.006	1.22 (1.17–1.28)	< 0.001	1.51 (1.44–1.58)	< 0.001
Age group											
< 35	1.39 (1.26–1.53)	< 0.001	1.09 (1.02–1.16)	0.015	1.00 [Ref]	1.09 (1.03-1.15)	0.001	1.24 (1.18–1.31)	< 0.001	1.51 (1.44–1.59)	< 0.001
≥35	1.39 (1.05–1.83)	0.022	0.97 (0.83-1.13)	0.669	1.00 [Ref]	0.99 (0.89–1.11)	0.964	1.16 (1.04–1.29)	0.007	1.49 (1.35–1.65)	< 0.001
Previous preterm t	oirths group										
No	1.41 (1.28–1.56)	< 0.001	1.07 (1.01–1.14)	0.053	1.00 [Ref]	1.06 (1.01–1.12)	0.031	1.22 (1.16–1.28)	< 0.001	1.51 (1.44–1.58)	< 0.001
Yes	1.24 (0.98–1.56)	0.067	1.07 (0.91–1.26)	0.390	1.00 [Ref]	1.14 (1.01–1.30)	0.059	1.23 (1.08–1.40)	0.002	1.51 (1.33–1.71)	< 0.001
Premature birth											
Total population	0.99 (0.44–2.24)	0.996	1.01 (0.61–1.68)	0.963	1.00 [Ref]	1.01 (0.68–1.49)	0.974	0.98 (0.67–1.44)	0:930	1.01 (0.69–1.48)	096.0
Age group											
< 35	1.01 (0.43–2.38)	0.976	1.02 (0.59–1.76)	0.940	1.00 [Ref]	1.01 (0.65–1.56)	0.974	0.98 (0.64–1.49)	0.918	1.01 (0.66–1.52)	0.996
≥ 35	0.93 (0.08–10.44)	0.956	0.98 (0.27–3.50)	0.972	1.00 [Ref]	1.01 (0.41–2.44)	0.998	0.99 (0.42–2.36)	0.990	1.01 (0.44–2.31)	0.980
Previous preterm ł	oirths group										
No	0.99 (0.42–2.35)	0.979	1.01 (0.59–1.73)	0.959	1.00 [Ref]	1.01 (0.66–1.52)	0.982	0.98 (0.66–1.47)	0.937	1.01 (0.68–1.51)	0.958
Yes	1.07 (0.12–9.69)	0.951	1.01 (0.23-4.44)	0.987	1.00 [Ref]	1.01 (0.31–3.36)	0.981	0.97 (0.30–3.15)	0.966	1.01 (0.31–3.26)	0.984
Apgar score at 5 mi	n < 7										
Total population	1.10 (0.96–1.28)	0.177	1.03 (0.94–1.14)	0.476	1.00 [Ref]	1.01 (0.93–1.08)	0.860	1.01 (0.94–1.08)	0.884	1.03 (0.95–1.10)	0.497
Age group											
< 35	1.08 (0.92–1.26)	0.345	1.03 (0.93–1.13)	0.631	1.00 [Ref]	1.01 (0.92–1.09)	0.996	0.98 (0.91–1.06)	0.638	0.98 (0.90–1.06)	0.592
≥ 35	1.49 (0.98–2.27)	0.061	1.12 (0.87–1.43)	0.385	1.00 [Ref]	1.03 (0.86–1.24)	0.730	1.10 (0.92–1.31)	0.291	1.11 (0.94–1.31)	0.214
Previous preterm {	oirths group										
No	1.12 (0.96–1.31)	0.151	1.03 (0.93–1.14)	0.544	1.00 [Ref]	1.01 (0.93–1.09)	0.892	0.99 (0.92–1.07)	0.868	1.03 (0.96–1.11)	0.417
Yes	1.03 (0.71–1.51)	0.862	1.06 (0.80–1.41)	0.674	1.00 [Ref]	1.02 (0.81–1.30)	0.836	1.11 (0.88–1.39)	0.377	0.96 (0.77–1.21)	0.734

	≤ 11 month		12~17 month		18~23 month	$24 \sim 35$ month		36 ~ 59 month		> 60 month	
	OR (95% CI)	Р	OR (95% CI)	٩	OR (95% CI)	OR (95% CI)	٩	OR (95% CI)	Ч	OR (95% CI)	Р
Abnormal conditio	ns of the newborn										
Total population	1.18 (1.11–1.25)	< 0.001	1.07 (1.03–1.11)	< 0.001	1.00 [Ref]	1.02 (0.99–1.05)	0.278	1.02 (0.99–1.05)	0.145	1.05 (1.02–1.08)	< 0.001
Age group											
< 35	1.18 (1.10–1.26)	< 0.001	1.06 (1.02–1.11)	0.003	1.00 [Ref]	1.02 (0.99–1.06)	0.207	1.02 (0.99–1.06)	0.194	1.06 (1.02–1.09)	< 0.001
≥ 35	1.14 (0.95–1.38)	0.162	1.08 (0.98–1.19)	0.102	1.00 [Ref]	1.01 (0.95–1.08)	0.731	1.04 (0.98–1.11)	0.211	1.08 (1.02–1.15)	0.011
Previous preterm I	births group										
No	1.17 (1.10–1.25)	< 0.001	1.07 (1.03-1.11)	0.001	1.00 [Ref]	1.01 (0.98–1.05)	0.352	1.02 (0.99–1.05)	0.135	1.06 (1.03–1.09)	< 0.001
Yes	1.20 (0.99–1.45)	0.061	1.09 (0.96–1.23)	0.204	1.00 [Ref]	1.02 (0.92–1.13)	0.669	0.99 (0.89–1.10)	0.845	0.99 (0.90–1.10)	0.885
OR odds ratio; Cl confic smoking during pregn age, clinical chorioamn	dence interval, <i>Ref</i> refer ancy, prenatal care, pre ionitis or maternal fev	ence; OR show 2-pregnancy BN er during labor,	s the results of multiva II, pre-pregnancy diab and previous preterm	ariate logistic betes, gestatio birth (unadju	egression analysis aft nal diabetes, pre-preç ısted in previous pret	ter adjusting for age (u gnancy hypertension, erm births group anal	unadjusted gestation h ysis)	in age group analysis) ypertension, eclamps	, race, weight ia, assisted rej	gain, smoking before oroductive treatment,	pregnancy, gestational

Interpregnancy interval

 Table 5 (continued)

 Outcome

odds ratio; C/ confidence interval, Ref reference; OR shows the results of multivariate logistic regression analysis after adjusting for age (unadjusted in age group analysis); race, weight gain, smoking before pregname
oking during pregnancy, prenatal care, pre-pregnancy BMI, pre-pregnancy diabetes, gestational diabetes, pre-pregnancy hypertension, gestation hypertension, eclampsia, assisted reproductive treatment, gestation
e, clinical chorioamnionitis or maternal fever during labor, and previous preterm birth (unadjusted in previous preterm births group analysis)

long IPI is maternal age. Long IPI increases maternal age, and women of advanced maternal age have a higher rate of cesarean delivery than non-advanced maternal age women [29, 30]. In addition, the effect of a long IPI on the risk of repeat cesarean delivery may be related to timelimited physiological adaptations of the reproductive system resulting from pregnancy (e.g., increased blood flow to the uterus) [8, 31]. As the interval between pregnancies increases, these adaptations may regress and maternal physiological characteristics may revert to those of primiparous women, which may cause an increase in the odds of cesarean delivery [8].

The relationship between IPI and maternal adverse events showed that a long IPI (≥ 60 months) was found to be associated with a decreased risk of maternal transfusion and ruptured uterus in women aged < 35 years. Previous studies demonstrated that women who gave birth for the first time at age 30 years or older had a shorter IPI compared to women who started childbearing at younger ages [32, 33]. However, our results were not consistent with those of previous studies [4, 22]. Garg et al. found that women with an IPI < 6 months were related to an increased risk of maternal transfusion compared to women with an IPI of 18-23 months, while no statistical significance was observed in women with an $IPI \ge 60$ months [22]. Silva et al. indicated that the risk of maternal transfusion followed a U-shaped curve with increasing IPI compared to IPI at 18–23 months [4]. Possible explanation for the inconsistency of our results was the difference in the study population and the adjusted confounders. Our study focused on women whose first pregnancy was by cesarean delivery and more comprehensively considered the effects of confounders such as pre-pregnancy BMI, weight gain, smoking status, and previous medical history. In addition, previous studies have not conducted stratified analysis according to age. In the association between IPI and adverse neonatal events, both short and long IPIs were related to an increased risk of neonatal adverse events, which was consistent with previous studies [5, 9, 24, 25]. Mignini et al. showed that longer intervals of >72 months was associated with pre-eclampsia, fetal death, and low birth weight [7]. Our results suggested that the effect of IPI on adverse neonatal events was more frequent in women aged < 35 years. Schummers et al. found that the risk of adverse fetal and infant outcomes was more pronounced in women aged 20 to 34 years than in women aged 35 years or older [12].

Our study explored the effect of IPI on maternal and neonatal outcomes in subsequent pregnancies in women whose first delivery was by cesarean delivery using largesample multicenter data from the NVSS database. However, our study also has several limitations. First, the study population of subjects whose first delivery was by Page 14 of 16

cesarean delivery reduced the sample size, which may have resulted in reduced statistical power to detect the association between IPI and maternal and neonatal outcomes. Second, this study only included pregnant women with 2 consecutive singleton pregnancies and a first delivery by cesarean delivery, and the results may not be generalizable to women with multiple deliveries or multiple cesarean deliveries. Third, pregnancy outcomes and possible influencing factors recorded in the medical records were included in this study as far as possible, but there were still some confounders such as cervical maturity, duration of labor, and information on vitamins/iron/ folic supplements were not recorded. Fourth, we did not consider the bias from the long study duration such as changes in obstetrical care/protocols during the study period. Fifth, although we considered clinical chorioamnionitis or maternal fever during labor as a confounder, other information on the risk of invasive placental diagnosis associated with IPI was not considered due to database limitations. Sixth, the mode of cesarean delivery, the number of layers for uterine closure, and the TOLAC protocols were not available due to the absence of relevant records in the database.

Conclusions

The associations between IPI and maternal and neonatal outcomes in subsequent pregnancies was investigated in women whose first delivery was by cesarean delivery. Both short and long IPI were associated with an increased risk of repeat cesarean delivery and neonatal adverse events. Among women aged < 35 years, an IPI more than 36 months after the first cesarean delivery was associated with a low risk of maternal transfusion and ruptured uterus.

Abbreviations

IPI	Interpregnancy interval
NICU	Neonatal intensive care unit
NVSS	National Vital Statistics System
NCHS	National Center for Health Statistics
BMI	Body mass index
ICU	Intensive care unit
SD	Standard deviation
OR	Odds ratio
CI	Confidence interval

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12884-023-05600-x.

Additional file 1: Supplement Table 1. Univariate logistic regression analysis between covariates and the risk of cesarean delivery. Supplement Table 2. Univariate logistic regression analysis between covariates and the risk of any maternal adverse events. Supplement Table 3. Univariate logistic regression analysis between covariates and the risk of any neonatal adverse events.

Acknowledgements

Not applicable.

Authors' contributions

HD, JC and LL designed the study. HD and JC wrote the manuscript. WW collected, analyzed and interpreted the data. LL critically reviewed, edited and approved the manuscript. All authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

The datasets generated and/or analyzed during the current study are available in the NVSS database, https://www.cdc.gov/nchs/nvss/index.htm.

Declarations

Ethics approval and consent to participate

The requirement of ethical approval for this was waived by the Institutional Review Board of The Second Medical Center of PLA General Hospital, because the data was accessed from NVSS (a publicly available database). All individuals provided written informed consent before participating in the study. All methods were carried out in accordance with relevant guidelines and regulations (declaration of Helsinki).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Children's Medical Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, People's Republic of China. ²Senior Department of Pediatrics, The Seventh Medical Center of PLA General Hospital, Beijing 100700, People's Republic of China. ³Department of Radiology, The Seventh Medical Center of PLA General Hospital, Beijing 100700, People's Republic of China. ⁴Department of Comprehensive Treatment, The Second Medical Center of PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100036, People's Republic of China.

Received: 15 December 2022 Accepted: 12 April 2023 Published online: 25 April 2023

References

- Shachar BZ, Mayo JA, Lyell DJ, Baer RJ, Jeliffe-Pawlowski LL, Stevenson DK, et al. Interpregnancy interval after live birth or pregnancy termination and estimated risk of preterm birth: a retrospective cohort study. BJOG. 2016;123:2009–17.
- Kangatharan C, Labram S, Bhattacharya S. Interpregnancy interval following miscarriage and adverse pregnancy outcomes: systematic review and meta-analysis. Hum Reprod Update. 2017;23:221–31.
- De Silva DA, Thoma ME. The association between interpregnancy interval and severe maternal morbidities using revised national birth certificate data: A probabilistic bias analysis. Paediatr Perinat Epidemiol. 2020;34:469–80.
- DeFranco EA, Seske LM, Greenberg JM, Muglia LJ. Influence of interpregnancy interval on neonatal morbidity. Am J Obstet Gynecol. 2015;212(386):e1-9.
- Hanley GE, Hutcheon JA, Kinniburgh BA, Lee L. Interpregnancy Interval and Adverse Pregnancy Outcomes: An Analysis of Successive Pregnancies. Obstet Gynecol. 2017;129:408–15.

- McKinney D, House M, Chen A, Muglia L, DeFranco E. The influence of interpregnancy interval on infant mortality. Am J Obstet Gynecol. 2017;216:316.e1-.e9.
- Mignini LE, Carroli G, Betran AP, Fescina R, Cuesta C, Campodonico L, et al. Interpregnancy interval and perinatal outcomes across Latin America from 1990 to 2009: a large multi-country study. BJOG. 2016;123:730–7.
- Kawakita T, Franco S, Ghofranian A, Thomas A, Landy HJ. Association between long interpregnancy intervals and cesarean delivery due to arrest disorders. Am J Obstet Gynecol MFM. 2020;2: 100103.
- Class QA, Rickert ME, Oberg AS, Sujan AC, Almqvist C, Larsson H, et al. Within-Family Analysis of Interpregnancy Interval and Adverse Birth Outcomes. Obstet Gynecol. 2017;130:1304–11.
- Stephansson O, Dickman PW, Cnattingius S. The influence of interpregnancy interval on the subsequent risk of stillbirth and early neonatal death. Obstet Gynecol. 2003;102:101–8.
- Marston C. Report of a WHO technical consultation on birth spacing. Geneva (Switzerland): World Health Organization; 2005. https://www. who.int/publications/i/item/WHO-RHR-07.1. Accessed 23 Sept 2022.
- Schummers L, Hutcheon JA, Hernandez-Diaz S, Williams PL, Hacker MR, VanderWeele TJ, et al. Association of short interpregnancy interval with pregnancy outcomes according to maternal age. JAMA Intern Med. 2018;178:1661–70.
- Van Winsen KD, Savvidou MD, Steer PJ. The effect of mode of delivery and duration of labour on subsequent pregnancy outcomes: a retrospective cohort study. BJOG. 2021;128:2132–9.
- Clark SL, Belfort MA, Dildy GA, Herbst MA, Meyers JA, Hankins GD. Maternal death in the 21st century: causes, prevention, and relationship to cesarean delivery. Am J Obstet Gynecol. 2008;199:36.e1-5 discussion 91–2. e7–11.
- Kjerulff KH, Paul IM, Weisman CS, Hillemeier MM, Wang M, Legro RS, et al. Association between mode of first delivery and subsequent fecundity and fertility. JAMA Netw Open. 2020;3: e203076.
- Martin JA, Hamilton BE, Osterman MJK, Driscoll AK. Births: Final Data for 2019. National vital statistics reports: from the centers for disease control and prevention, National Center for Health Statistics, National Vital Statistics System. 2021;70:1–51.
- 17. Boyle A, Reddy UM. Epidemiology of cesarean delivery: the scope of the problem. Semin Perinatol. 2012;36:308–14.
- Menacker F, Declercq E, Macdorman MF. Cesarean delivery: background, trends, and epidemiology. Semin Perinatol. 2006;30:235–41.
- Ye L, Cao W, Yao J, Peng G, Zhou R. Systematic review of the effects of birth spacing after cesarean delivery on maternal and perinatal outcomes. Int J Gynaecol Obstet. 2019;147:19–28.
- Cunningham S, Algeo CE, DeFranco EA. Influence of interpregnancy interval on uterine rupture. J Matern Fetal Neonatal Med. 2021;34:2848–53.
- Stamilio DM, DeFranco E, Paré E, Odibo AO, Peipert JF, Allsworth JE, et al. Short interpregnancy interval: risk of uterine rupture and complications of vaginal birth after cesarean delivery. Obstet Gynecol. 2007;110:1075–82.
- Garg B, Darney B, Pilliod RA, Caughey AB. Long and short interpregnancy intervals increase severe maternal morbidity. Am JObstet Gynecol;225:331.e1-.e8.
- Xu T, Miao H, Chen Y, Luo L, Guo P, Zhu Y. Association of interpregnancy interval with adverse birth outcomes. JAMA Netw Open. 2022;5:e2216658
- Chen I, Jhangri GS, Chandra S. Relationship between interpregnancy interval and congenital anomalies. Am J Obstet Gynecol. 2014;210(564):e1-8.
- Ahrens KA, Nelson H, Stidd RL, Moskosky S, Hutcheon JA. Short interpregnancy intervals and adverse perinatal outcomes in high-resource settings: an updated systematic review. Paediatr Perinat Epidemiol. 2019;33:O25-o47.
- 26. Keag OE, Norman JE, Stock SJ. Long-term risks and benefits associated with cesarean delivery for mother, baby, and subsequent pregnancies: systematic review and meta-analysis. PLoS Med. 2018;15.
- Saleh AM, Dudenhausen JW, Ahmed B. Increased rates of cesarean sections and large families: a potentially dangerous combination. J Perinat Med. 2017;45:517–21.

- Morton R, Burton AE, Kumar P, Hyett JA, Phipps H, McGeechan K, et al. Cesarean delivery: Trend in indications over three decades within a major city hospital network. Acta Obstet Gynecol Scand. 2020;99:909–16.
- de Vries BS, Morton R, Burton AE, Kumar P, Hyett JA, Phipps H, McGeechan K. Attributable factors for the rising cesarean delivery rate over 3 decades: an observational cohort study. Am J Obstet Gynecol MFM. 2022;4: 100555.
- Osmundson SS, Gould JB, Butwick AJ, Yeaton-Massey A, El-Sayed YY. Labor outcome at extremely advanced maternal age. Am J Obstet Gynecol. 2016;214(362):e1-7.
- Zhu BP, Rolfs RT, Nangle BE, Horan JM. Effect of the interval between pregnancies on perinatal outcomes. N Engl J Med. 1999;340:589–94.
- Cheslack Postava K, Winter AS. Short and long interpregnancy intervals: correlates and variations by pregnancy timing among U.S. women. Perspect Sex Reprod Health. 2015;47:19–26.
- Gemmill A, Lindberg LD. Short interpregnancy intervals in the United States. Obstet Gynecol. 2013;122:64–71.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

